joining us now on a first on cnbc interview is structure therapeutics ceo ray stevens. you for being on the show. >> thank you very much for having me on the show, melissa. i'm excited to be here to talk about structure therapeutic and the release last week. >> how are you thinking of the niche that this oral pill will fill? on the conference call with analysts it sounds like you're positioning it as a direct com competitor to the oral offerings that lilly is offering and novo is researching. or a maintenance drug. how should we think of it? >> the drug we created is an oral small molecule. think about ibuprofen, advil, lipitor, your blood pressure lowering medication. these are small molecules and the reason why i emphasize that point is one of the advantages small molecules have is we have the ability it scale, so we can make enough material for more than 100 million people. today in 2023, only 5 million people are able to get access in the united states alone and so the scaling is really, really important. secondly, in terms of positioning, you know, we look at this